Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma.
Rousseau B, Guillemin A, Duvoux C, Neuzillet C, Tlemsani C, Compagnon P, Azoulay D, Salloum C, Laurent A, de la Taille A, Salomon L, Cholley I, Haioun C, Dupuis J, Wolkenstein P, Matignon MB, Grimbert P, Tournigand C.
Rousseau B, et al.
Int J Cancer. 2019 Feb 15;144(4):886-896. doi: 10.1002/ijc.31769. Epub 2018 Nov 20.
Int J Cancer. 2019.
PMID: 30155929